Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.

ND02 is under clinical development by HK inno.N and currently in Phase II for Glaucoma. According to GlobalData, Phase II drugs for Glaucoma have a 39% phase transition success rate (PTSR) indication ...

Sodium calcium edetate + tobramycin is under clinical development by Respirion Pharmaceuticals and currently in Phase II for Cystic Fibrosis.

Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer.

Anti-CD22-CAR is under clinical development by Kecellitics Biotech and currently in Phase II for B-Cell Non-Hodgkin Lymphoma.

PF-08046040 is under clinical development by Pfizer and currently in Phase I for Relapsed Acute Myeloid Leukemia.

PTG-007 is under clinical development by PolTREG and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes).

MAQ-001 is under development for the treatment of advanced solid tumors. The therapeutic candidate is an anti-PD1 monoclonal antibody and is being administered through intravenous route. For a ...

DC-806 is under clinical development by DICE Therapeutics and currently in Phase I for Unspecified Immunological Disorders.

NVXCoV-2540 is under clinical development by Novavax and currently in Phase III for Coronavirus Disease 2019 (COVID-19).